Infor, which makes large-scale cloud ERP software, has been around since 2002 and counts Koch as both a customer and an investor, so the deal makes sense on that level. Koch was lead investor last year in a $1.5 billion investment, wherein the company indicated that it was a step before going public.
Esperion, which is based in Ann Arbor, Mich., said the drug’s brand name will be Nexletol. Esperion also has applied to the FDA for approval of a combination pill of bempedoic acid and ezetimibe, a non-statin pill approved in 2002. In studies, the combination pill reduced cholesterol by about 38 to 44 percent, depending on whether a person was taking a statin and how much, the company said. The FDA decision is expected shortly.